The video talk series provides insights into the use of biosimilar medicines across various specialty areas, including oncology, rheumatology, gastroenterology, haematology, dermatology and hospital pharmacy.
areas for biosimilar medicines include:
- Safety and efficacy
- Clinical experience
- Approval and regulation
- Benefits of biosimilar medicines.
A FOCUS ON PEER-TO-PEER DISCUSSION AND EXPERIENCE
Join fellow healthcare professionals from across Australia for a peer-to-peer exchange of knowledge and clinical experience with biosimilar medicines.
Chief Pharmacist, Royal Marsden NHS Foundation Trust
Jatinder Harchowal provides an international perspective on the use of biosimilar medicines in the United Kingdom.
Chief Medical Officer, Australian Government
Professor Brendan Murphy is the Chief Medical Officer for the Australian Government and is the principal medical adviser to the Minister and the Department of Health.
Prof Bird has over twenty years' experience in treating rheumatic disease, with particular expertise in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
A/Prof Östör MD, MA, MB BS, FRACP, FRCP, FRCP (Edin), is a Consultant Rheumatologist at Cabrini Medical Centre and Principle Investigator at Emeritus Research, Melbourne.
Prof Szer has particular expertise in malignant haematology and haemopoietic stem cell transplantation, which he established as a form of therapy in Victoria in the early 1980s.
Prof Zalcberg is Head of the Cancer Research Program in the School of Public Health and Preventive Medicine at Monash University.
Prof Clarke is a medical oncologist, pharmacologist and translational researcher with major clinical and research interests in gastrointestinal and thoracic cancers.
Prof Sinclair is Professor of Dermatology at the University of Melbourne and Director of Epworth Dermatology. He is past-president of the Australasian Society for Dermatology Research.
Dr Thin is a consultant gastroenterologist at Fiona Stanley Hospital, a position she has held for 8 years. Dr Thin is the lead clinical trials investigator for the IBD unit.
Dr Ghaly is Head of the Inflammatory Bowel Disease Service and Staff Specialist at St. Vincent’s Hospital, Sydney. He is also a lecturer at the School of Medicine, UNSW Sydney.
Executive Director Pharmacy and Redevelopment, North East Health, and owner and Director, David Ford Healthcare Consulting.
Barry has enjoyed a diverse career beginning in community pharmacy and moving into regional and remote hospital pharmacy in WA and far North QLD.
Listen to various experts discuss the potential cost savings and benefits of biosimilar medicines in Australia.
Listen to various experts discuss the approval and regulation of biosimilar medicines.
Listen to various experts discuss the safety and efficacy of biosimilar medicines.
Listen to various experts discuss the current clinical experience with biosimilar medicines.